Moleculin Biotech (MBRX) Posts Quarterly Earnings Results

Maricruz Casares
May 17, 2018

About MOLECULIN BIOTECH, INC.

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. (NASDAQ:MBRX) news were brought out by Globenewswire.com, Streetinsider.com and Nasdaq.com. Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been created to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. ValuEngine raised shares of Moleculin Biotech from a "strong sell" rating to a "sell" rating in a report on Friday, February 2nd. Wall Street now sees -17.65 % EPS growth despite Moleculin Biotech, Inc. previous quarter's EPS of $-0.17. The company had a trading volume of 174,300 shares, compared to its average volume of 759,656. MBRX is reaching $1.77 during the last trading session, after increased 1.72%.Moleculin Biotech, Inc. has volume of 9,070 shares.

More news: ¡Laura G vive terrible momento en Todo un Show!

EX-99.1 2 exh991-financials33118q120.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Moleculin Biotech, ... This year's earnings per share analyst estimate is anticipated to be $-0.14. The company has a market cap of $44.84 million, a price-to-earnings ratio of -3.70 and a beta of -0.88. The first one has "Moleculin Biotech (MBRX) Enters Pact with BSP Pharmaceuticals for its Leukemia Drug Candidate" as a title and was announced on April 24, 2018. The Company's lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia.Last it reported negative earnings. The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO